High-performance exosome extraction improves DMD therapy

News July 15, 2025

The exosome extraction technology has brought significant advancements to medicine, especially in the development of cell therapies for genetic diseases. The collaboration between Huixin Biopharma and Capricor Therapeutics is a prime example. They have jointly applied the EXODUS automatic exosome extraction system in treatments, which could improve genetic and chronic conditions, particularly in the treatment of Duchenne muscular dystrophy (DMD).

 

High-performance exosome extraction improves DMD treatment
High-performance exosome extraction improves DMD treatment

Introduction to Huixin Biopharma and Capricor Therapeutics

In a strategic move to promote the development of exosome therapy in the biomedical industry, Huixin Biopharma has partnered with Capricor Therapeutics, a leading US biotechnology company. Huixin Biopharma has recently completed the installation and delivery of the EXODUS automatic exosome extraction system, an advanced product that enhances the process of exosome separation and purification. This system plays a critical role in exosome therapy research and development, offering new hope for treating severe genetic disorders, particularly Duchenne muscular dystrophy (DMD).

EXODUS exosome extraction technology: A breakthrough in exosome therapy research

Exosomes, micro-particles produced by cells, have quickly become a focus of biomedical research. They play an important role in transmitting signals between cells and can carry biological factors that may alter disease processes. Therefore, extracting and purifying exosomes with high purity is crucial for developing exosome therapies.

The EXODUS exosome extraction system provided by Huixin Biopharma is a fully automated device that optimizes the process of exosome separation and purification, minimizing risks from external factors and ensuring maximum exosome quality. This technology offers an effective solution for companies researching and developing exosome therapies, supporting the industrialization of this treatment.

Capricor Therapeutics and progress in exosome therapy for DMD treatment

Capricor Therapeutics is a publicly listed biotechnology company in the US, specializing in the development of exosome and cell therapies for severe diseases, including Duchenne muscular dystrophy (DMD). DMD is a severe genetic disease affecting muscles, the heart, and the respiratory system, leading to physical weakness and death at a young age.

Capricor is developing an exosome therapy called CAP-1002 to treat DMD. This therapy uses exosomes containing bioactive substances from human-derived cardiac stem cells (CDC). The exosomes help modulate the immune system, reduce inflammation, and slow fibrosis, thereby slowing disease progression and stimulating tissue regeneration.

On June 11, 2024, Capricor announced the successful completion of a Type B meeting with the US Food and Drug Administration (FDA) to discuss the next steps for the biologics license application (BLA) for CAP-1002. This is a significant milestone, paving the way for Capricor to submit the BLA in Q3 2024. Capricor is close to the potential approval and commercialization of this exosome therapy.

Exosome therapy development process

CAP-1002 has gained widespread recognition in the medical community, with the World Health Organization (WHO) assigning the international nonproprietary name (INN) “deramiocel” to the product. This marks a significant step in the global recognition and development of exosome therapy.

With the ongoing BLA filing process, Capricor plans to present critical clinical data from the HOPE-2 and HOPE-3 studies shortly. Notably, three-year data from the HOPE-2 OLE study will be presented at the PPMD meeting to demonstrate the effectiveness and safety of CAP-1002.

Duchenne muscular dystrophy (DMD): The urgent need for new therapies

Duchenne muscular dystrophy (DMD) is a rare genetic disorder that primarily affects boys, leading to progressive muscle loss, impaired movement, breathing difficulties, and heart function. Patients typically die before the age of 30, and there is currently no definitive cure.

One of the main causes of DMD is the lack of dystrophin, an essential protein in muscles. The deficiency of dystrophin leads to muscle cell damage and fibrosis, causing rapid physical decline. Current DMD treatments are limited, and the advent of CAP-1002 offers new hope for DMD patients.

The bright future of exosome cell therapy

Exosomes have attracted significant attention in the biotechnology industry due to their ability to transport essential biological factors, helping to treat various conditions, from cancer to genetic diseases like DMD. Although exosome technology is still in the development phase, advancements in R&D and clinical trials have shown the vast potential of this field.

Huixin Biopharma not only provides the EXODUS automatic exosome extraction system but also collaborates with other companies to rapidly develop exosome technology. This is a positive sign for the biomedical industry, particularly in treating DMD and other genetic disorders.

Conclusion

The collaboration between Huixin Biopharma and Capricor Therapeutics marks a major step forward in the biomedical industry, particularly in developing exosome cell therapies for Duchenne muscular dystrophy (DMD). The EXODUS automatic exosome extraction system will play an important role in enhancing exosome production and purification, thus accelerating the industrialization of exosome therapies.

With the rapid development of exosome technology and significant clinical research achievements, exosome therapy will become an effective treatment option for many genetic and chronic diseases, bringing hope to millions of patients worldwide.

Summary introduction to Huixin Biopharma and EXODUS

Huixin Biopharma is a company specializing in providing advanced biotechnology solutions, particularly in the field of exosome extraction. The company develops and supplies the EXODUS automatic exosome extraction system, which optimizes the exosome separation and purification process, improving efficiency and minimizing errors caused by human factors. EXODUS uses modern technology to increase accuracy and reduce the time required for exosome extraction, with widespread applications in cell therapy, exosome therapy, and the treatment of genetic diseases, cancer, and chronic conditions.

Biogroup Vietnam is the official distributor of the EXODUS system in Vietnam. The company specializes in providing advanced biological solutions, supporting research and production of cells, stem cells, and biomolecules. Biogroup is committed to providing technical consulting services and after-sales support, working alongside customers to develop biotechnology in Vietnam.

 

 Contact us for consultation on the EXODUS automatic exosome extraction system

 

References

  1. eMedClub News.